Placebo to izokibep

DRUG2 trials

Sponsors

ACELYRIN Inc.

Conditions

Hidradenitis SuppurativaPsoriatic Arthritis

Phase 2

Hidradenitis Suppurativa Phase 2b Study of Izokibep

CompletedNCT05355805

ACELYRIN Inc.Hidradenitis Suppurativa

Start: 2022-05-05End: 2024-02-21Updated: 2025-06-03

Psoriatic Arthritis Study of Izokibep

TerminatedNCT05623345

ACELYRIN Inc.Psoriatic Arthritis

Start: 2022-11-21End: 2024-08-08Updated: 2025-05-23

Related Papers

Small protein targeting IL-17A effective in PsA management

2024-07-29

Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

mAbs2023-05-1553 citations